Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
pazopanib (Votrient®)
Reference No. 549
Publication date:
03/12/2013
Last review date:
01/12/2016
Appraisal information
pazopanib (Votrient®) 200 mg film-coated tablet
pazopanib (Votrient®) 400 mg film-coated tablet
Company:
Novartis Pharmaceuticals UK Ltd
BNF category:
Malignant disease and immunosupression
NMG meeting date:
20/02/2013
AWMSG meeting date:
16/10/2013
Submission Type:
Independent Review
Status:
Recommended
Advice No:
2513
Ministerial ratification:
02/12/2013
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification
AWMSG advice
Pazopanib (Votrient®) is recommended as an option for use within NHS Wales for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
pazopanib (Votrient) 549 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
pazopanib (Votrient) 549 ASAR
Clinical Expert (CE) Summary
Download
pazopanib (Votrient) 549 CE summary
